MA52861A - Méthodes et compositions pour le traitement de l'apnée du sommeil - Google Patents
Méthodes et compositions pour le traitement de l'apnée du sommeilInfo
- Publication number
- MA52861A MA52861A MA052861A MA52861A MA52861A MA 52861 A MA52861 A MA 52861A MA 052861 A MA052861 A MA 052861A MA 52861 A MA52861 A MA 52861A MA 52861 A MA52861 A MA 52861A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- treatment
- methods
- sleep apnea
- apnea
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 201000002859 sleep apnea Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862623892P | 2018-01-30 | 2018-01-30 | |
| EP19705634.4A EP3746126B1 (fr) | 2018-01-30 | 2019-01-30 | Méthodes et compositions pour le traitement de l'apnée du sommeil ou le ronflement simple |
| PCT/US2019/015781 WO2019152475A1 (fr) | 2018-01-30 | 2019-01-30 | Méthodes et compositions pour le traitement de l'apnée du sommeil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA52861A true MA52861A (fr) | 2021-05-05 |
| MA52861B1 MA52861B1 (fr) | 2024-09-30 |
Family
ID=65441079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA52861A MA52861B1 (fr) | 2018-01-30 | 2019-01-30 | Méthodes et compositions pour le traitement de l'apnée du sommeil ou le ronflement simple |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US11911351B2 (fr) |
| EP (2) | EP3746126B1 (fr) |
| JP (3) | JP7422666B2 (fr) |
| KR (2) | KR20250156197A (fr) |
| CN (2) | CN118384147A (fr) |
| AU (2) | AU2019214891B2 (fr) |
| BR (1) | BR112020015316A2 (fr) |
| CA (1) | CA3089712A1 (fr) |
| DK (1) | DK3746126T3 (fr) |
| EA (1) | EA202091597A1 (fr) |
| ES (1) | ES2991425T3 (fr) |
| FI (1) | FI3746126T3 (fr) |
| HR (1) | HRP20241412T1 (fr) |
| HU (1) | HUE068505T2 (fr) |
| IL (1) | IL276247A (fr) |
| LT (1) | LT3746126T (fr) |
| MA (1) | MA52861B1 (fr) |
| MD (1) | MD3746126T2 (fr) |
| MX (2) | MX2020008086A (fr) |
| PL (1) | PL3746126T3 (fr) |
| PT (1) | PT3746126T (fr) |
| RS (1) | RS66104B1 (fr) |
| SG (1) | SG11202007226UA (fr) |
| SI (1) | SI3746126T1 (fr) |
| SM (1) | SMT202400400T1 (fr) |
| UA (1) | UA129618C2 (fr) |
| WO (1) | WO2019152475A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEAP202416602A (en) | 2017-04-28 | 2024-10-10 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea |
| EA202192202A1 (ru) | 2019-02-08 | 2021-11-03 | Дзе Брихэм Энд Уимен'З Хоспитал, Инк. | Способы и композиции для лечения синдрома обструктивного апноэ, возникающего во сне |
| US20220362221A1 (en) * | 2019-11-04 | 2022-11-17 | Apnimed, Inc. (Delaware) | Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea |
| CN116391233A (zh) * | 2020-09-30 | 2023-07-04 | 皇家飞利浦有限公司 | 用于执行剂量滴定的方法和系统 |
| CA3210092A1 (fr) * | 2021-03-04 | 2022-09-09 | Lawrence G. Miller | Combinaison de reboxetine et d'un antagoniste du recepteur muscarinique (arm) destinee a etre utilisee dans le traitement de l'apnee du sommeil |
| KR20230159462A (ko) * | 2021-03-24 | 2023-11-21 | 애프니메드, 인코포레이티드 (델라웨어) | 수면 무호흡증 치료 방법 및 조성물 |
| EP4334281A1 (fr) | 2021-05-04 | 2024-03-13 | Apnimed, Inc. (Delaware) | Formes solides de (r)-oxybutynine d-malate |
| IL309251A (en) * | 2021-06-17 | 2024-02-01 | Apnimed Inc Delaware | Norepinephrine reuptake inhibitors for the treatment of sleep apnea |
| CA3259602A1 (fr) | 2021-12-22 | 2023-06-29 | Bayer Aktiengesellschaft | Combinaison d’un antagoniste alpha 2-adrénocepteur de sous-type c (alpha-2 c) et d’un antagoniste du récepteur muscarinique pour le traitement de l’apnée du sommeil |
| KR20240124995A (ko) | 2021-12-22 | 2024-08-19 | 바이엘 악티엔게젤샤프트 | 수면 무호흡의 치료를 위한 a2-아드레날린수용체 하위유형 c (알파-2c) 길항제와 노르에피네프린 재흡수 억제제의 조합물 |
| US20250302814A1 (en) * | 2022-05-13 | 2025-10-02 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| KR20250000641A (ko) * | 2023-06-27 | 2025-01-03 | 주식회사 아스트로젠 | 수면장애 및/또는 수면장애 관련 질환을 예방, 개선 또는 치료하는 방법 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL267508A (fr) | 1960-07-26 | |||
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPH11515015A (ja) | 1995-10-24 | 1999-12-21 | グルーエネンタール ゲゼルシャフト ミット ベシュレンクテル ハフツング | 睡眠無呼吸の抑止方法 |
| CN1660435A (zh) * | 2000-02-24 | 2005-08-31 | 法玛西雅厄普约翰美国公司 | 新的药物联合形式 |
| US20020155113A1 (en) | 2001-03-13 | 2002-10-24 | Miyoung Chun | Methods for treating or preventing cardiovascular disorders by modulating metalloprotease function |
| US20030060513A1 (en) | 2001-09-27 | 2003-03-27 | Arneric Stephen P. | Pharmaceutical composition |
| US20030185882A1 (en) * | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
| US20040235925A1 (en) | 2002-12-17 | 2004-11-25 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| CA2523567A1 (fr) | 2003-04-25 | 2004-11-11 | Indevus Pharmaceuticals, Inc. | Procede destine a favoriser un sommeil ininterrompu par l'administration d'un chlorure de trospium |
| WO2005063254A2 (fr) | 2003-12-22 | 2005-07-14 | Acadia Pharmaceuticals Inc. | Analogues de diaryl[a,d]cycloheptene amino substitues utilises comme agonistes muscariniques, et procedes de traitement de troubles neuropsychiatriques |
| US20060039866A1 (en) | 2004-08-20 | 2006-02-23 | Cypress Bioscience, Inc. | Method for treating sleep-related breathing disorders |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| EP1827450A4 (fr) | 2004-11-17 | 2009-04-22 | Cypress Bioscience Inc | Methodes servant a limiter les effets secondaires d'un traitement par mirtazapine |
| AU2005319367B2 (en) | 2004-12-20 | 2012-05-24 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
| CA2646729A1 (fr) | 2005-03-21 | 2006-09-28 | Dov Pharmaceutical, Inc. | Methodes et compositions destinees au traitement de l'incontinence urinaire |
| CA2603920A1 (fr) | 2005-04-15 | 2006-10-26 | The Board Of Trustees Of The University Of Illinois | Traitement pharmacologique pour le traitement des apnees du sommeil |
| US20070021921A1 (en) | 2005-07-21 | 2007-01-25 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Selective resonance of chemical structures |
| FR2889811B1 (fr) | 2005-08-19 | 2009-10-09 | Sanofi Aventis Sa | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique. |
| HUE032743T2 (en) | 2006-11-22 | 2017-10-30 | Clinical Res Ass Llc | A method for treating Down syndrome, fragilis X syndrome and autism |
| WO2008122019A1 (fr) | 2007-04-02 | 2008-10-09 | Cypress Biosciences, Inc. | Amélioration de la tolérabilité de la mirtazapine et de la réboxétine par leur utilisation en combinaison |
| AR065989A1 (es) | 2007-04-09 | 2009-07-15 | Sepracor Inc | Metodos y composiciones para el tratamiento de trastornos de la respiracion relacionados con el sueno |
| US8415390B2 (en) | 2008-05-30 | 2013-04-09 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| US20090048233A1 (en) | 2007-08-16 | 2009-02-19 | Cypress Biosciences, Inc. | Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination |
| CN101925349A (zh) | 2007-12-21 | 2010-12-22 | 欧兰德股份有限公司 | 替马西泮的口腔崩解片组合物 |
| US20100204058A1 (en) | 2009-01-28 | 2010-08-12 | Howard Yuan-Hao Chang | Profiling for Determination of Response to Treatment for Inflammatory Disease |
| CA2795253A1 (fr) | 2010-04-01 | 2011-10-06 | Theravida, Inc. | Procedes d'amelioration de la qualite du sommeil |
| EP2672972B1 (fr) | 2011-01-28 | 2020-11-04 | Pfantastic Medical Research Institute, LLC | Procédés pour traiter l'apnée obstructive du sommeil |
| JP2012176958A (ja) * | 2012-04-20 | 2012-09-13 | Watson Pharmaceuticals Inc | （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置 |
| US20160008334A1 (en) | 2013-03-05 | 2016-01-14 | Requis Pharmaceuticals Inc. | Preparations for the Treatment of Sleep-Related Respiratory Disorders |
| WO2016062265A1 (fr) | 2014-10-24 | 2016-04-28 | 朗齐生物医学股份有限公司 | Utilisation du monobenzone pour la préparation d'une composition pharmaceutique indiquée pour le traitement du cancer |
| HRP20192044T1 (hr) | 2015-04-27 | 2020-02-07 | Arena Pharmaceuticals, Inc. | Agonisti i pripravci 5-ht2c receptora i metode uporabe |
| ES2925951T3 (es) | 2015-07-22 | 2022-10-20 | John Hsu | Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso |
| WO2017031319A1 (fr) | 2015-08-18 | 2017-02-23 | Massachusetts Institute Of Technology | Traitement par médicament noradrénergique de l'apnée obstructive du sommeil |
| GEAP202416602A (en) * | 2017-04-28 | 2024-10-10 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea |
| AU2019216257B2 (en) | 2018-01-31 | 2025-11-20 | Research Institute At Nationwide Children's Hospital | Gene therapy for limb-girdle muscular dystrophy type 2C |
| EA202192202A1 (ru) | 2019-02-08 | 2021-11-03 | Дзе Брихэм Энд Уимен'З Хоспитал, Инк. | Способы и композиции для лечения синдрома обструктивного апноэ, возникающего во сне |
-
2019
- 2019-01-30 SI SI201930847T patent/SI3746126T1/sl unknown
- 2019-01-30 ES ES19705634T patent/ES2991425T3/es active Active
- 2019-01-30 MA MA52861A patent/MA52861B1/fr unknown
- 2019-01-30 HU HUE19705634A patent/HUE068505T2/hu unknown
- 2019-01-30 CN CN202410467832.8A patent/CN118384147A/zh active Pending
- 2019-01-30 WO PCT/US2019/015781 patent/WO2019152475A1/fr not_active Ceased
- 2019-01-30 DK DK19705634.4T patent/DK3746126T3/da active
- 2019-01-30 FI FIEP19705634.4T patent/FI3746126T3/fi active
- 2019-01-30 PT PT197056344T patent/PT3746126T/pt unknown
- 2019-01-30 KR KR1020257034519A patent/KR20250156197A/ko active Pending
- 2019-01-30 BR BR112020015316-8A patent/BR112020015316A2/pt unknown
- 2019-01-30 SM SM20240400T patent/SMT202400400T1/it unknown
- 2019-01-30 LT LTEPPCT/US2019/015781T patent/LT3746126T/lt unknown
- 2019-01-30 JP JP2020542075A patent/JP7422666B2/ja active Active
- 2019-01-30 EP EP19705634.4A patent/EP3746126B1/fr active Active
- 2019-01-30 UA UAA202004819A patent/UA129618C2/uk unknown
- 2019-01-30 HR HRP20241412TT patent/HRP20241412T1/hr unknown
- 2019-01-30 MX MX2020008086A patent/MX2020008086A/es unknown
- 2019-01-30 CN CN201980010884.XA patent/CN111670050A/zh active Pending
- 2019-01-30 RS RS20241137A patent/RS66104B1/sr unknown
- 2019-01-30 KR KR1020207024790A patent/KR102874891B1/ko active Active
- 2019-01-30 AU AU2019214891A patent/AU2019214891B2/en active Active
- 2019-01-30 EA EA202091597A patent/EA202091597A1/ru unknown
- 2019-01-30 MD MDE20201230T patent/MD3746126T2/ro unknown
- 2019-01-30 SG SG11202007226UA patent/SG11202007226UA/en unknown
- 2019-01-30 CA CA3089712A patent/CA3089712A1/fr active Pending
- 2019-01-30 EP EP24183712.9A patent/EP4445951A3/fr active Pending
- 2019-01-30 PL PL19705634.4T patent/PL3746126T3/pl unknown
- 2019-01-30 US US16/965,960 patent/US11911351B2/en active Active
-
2020
- 2020-07-23 IL IL276247A patent/IL276247A/en unknown
- 2020-07-30 MX MX2024001713A patent/MX2024001713A/es unknown
-
2022
- 2022-08-05 US US17/882,318 patent/US20220378724A1/en not_active Abandoned
-
2023
- 2023-10-25 JP JP2023183525A patent/JP2023181322A/ja active Pending
-
2024
- 2024-01-23 US US18/419,974 patent/US20240156753A1/en not_active Abandoned
- 2024-08-06 US US18/795,245 patent/US20240390299A1/en not_active Abandoned
- 2024-10-25 AU AU2024227631A patent/AU2024227631A1/en active Pending
-
2025
- 2025-02-17 US US19/055,172 patent/US20250186371A1/en not_active Abandoned
- 2025-08-22 JP JP2025138640A patent/JP2025159230A/ja active Pending
- 2025-10-02 US US19/348,331 patent/US20260027070A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52861A (fr) | Méthodes et compositions pour le traitement de l'apnée du sommeil | |
| EP3615016A4 (fr) | Procédés et compositions pour le traitement d'apnée du sommeil | |
| EP3924481A4 (fr) | Compositions et méthodes de traitement d'hémoglobinopathies | |
| EP3920898A4 (fr) | Méthodes et compositions pour le traitement de l'apnée du sommeil | |
| EP3630072A4 (fr) | Procédés et compositions pour le traitement d'une somnolence excessive | |
| EP3612215A4 (fr) | Compositions et procédés pour le traitement d'inflammation pulmonaire | |
| MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
| EP3528852A4 (fr) | Méthodes et compositions pour le traitement de la maladie de fabry | |
| EP3402533A4 (fr) | Méthodes et compositions pour le traitement d'une maladie neurologique | |
| EP3634431A4 (fr) | Compositions et méthodes thérapeutiques pour le traitement de l'hépatite b | |
| MA52631A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| EP3762505A4 (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| EP3810091A4 (fr) | Méthodes et compositions pour le traitement de l'hypertension pulmonaire | |
| EP3641746A4 (fr) | Méthodes et compositions pour le traitement d'une infection microbienne | |
| EP3866790A4 (fr) | Méthodes et compositions permettant le traitement du glaucome et d'affections apparentées | |
| MA49576A (fr) | Compositions et méthodes pour le traitement d'infections fongiques | |
| EP3400008A4 (fr) | Compositions thérapeutiques et méthodes pour le traitement de l'hépatite b | |
| EP3368048A4 (fr) | Méthodes et compositions pour le traitement de l'amyloïdose | |
| EP3638270A4 (fr) | Compositions et méthodes pour l'amélioration d'un traitement par hyperthermie | |
| EP3654961A4 (fr) | Méthodes et compositions pour le traitement de la douleur à l'aide de la capsaïcine | |
| EP3893902A4 (fr) | Compositions et méthodes utiles pour le traitement du cancer colorectal d'aspect crénelé | |
| EP3373922A4 (fr) | Compositions et méthodes pour le traitement de l'homocystinurie | |
| EP3518951A4 (fr) | Compositions et méthodes pour le traitement d'affections orthopédiques | |
| EP3638287A4 (fr) | Méthodes et compositions pour le traitement d'une inflammation microbienne | |
| EP3675846A4 (fr) | Méthodes et compositions de traitement d'une infection et d'une inflammation avec du sélénocyanate |